323 related articles for article (PubMed ID: 33077895)
21. Quality of life in Barth syndrome.
Kim AY; Vernon H; Manuel R; Almuqbil M; Hornby B
Ther Adv Rare Dis; 2022; 3():26330040221093743. PubMed ID: 37180415
[TBL] [Abstract][Full Text] [Related]
22. Phospholipid abnormalities in children with Barth syndrome.
Schlame M; Kelley RI; Feigenbaum A; Towbin JA; Heerdt PM; Schieble T; Wanders RJ; DiMauro S; Blanck TJ
J Am Coll Cardiol; 2003 Dec; 42(11):1994-9. PubMed ID: 14662265
[TBL] [Abstract][Full Text] [Related]
23. N-oleoylethanolamide treatment of lymphoblasts deficient in Tafazzin improves cell growth and mitochondrial morphology and dynamics.
Chan JZ; Fernandes MF; Steckel KE; Bradley RM; Hashemi A; Groh MR; Sciaini G; Stark KD; Duncan RE
Sci Rep; 2022 Jun; 12(1):9466. PubMed ID: 35676289
[TBL] [Abstract][Full Text] [Related]
24. Promotion of plasmalogen biosynthesis reverse lipid changes in a Barth Syndrome cell model.
Bozelli JC; Lu D; Atilla-Gokcumen GE; Epand RM
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Jun; 1865(6):158677. PubMed ID: 32126285
[TBL] [Abstract][Full Text] [Related]
25. NAD supplementation improves mitochondrial performance of cardiolipin mutants.
Ji J; Damschroder D; Bessert D; Lazcano P; Wessells R; Reynolds CA; Greenberg ML
Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Apr; 1867(4):159094. PubMed ID: 35051613
[TBL] [Abstract][Full Text] [Related]
26. Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice.
Russo S; De Rasmo D; Signorile A; Corcelli A; Lobasso S
Sci Rep; 2022 Nov; 12(1):19847. PubMed ID: 36400945
[TBL] [Abstract][Full Text] [Related]
27. Increased mtDNA Abundance and Improved Function in Human Barth Syndrome Patient Fibroblasts Following AAV-
Suzuki-Hatano S; Sriramvenugopal M; Ramanathan M; Soustek M; Byrne BJ; Cade WT; Kang PB; Pacak CA
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336787
[TBL] [Abstract][Full Text] [Related]
28. Cardiolipin and monolysocardiolipin analysis in fibroblasts, lymphocytes, and tissues using high-performance liquid chromatography-mass spectrometry as a diagnostic test for Barth syndrome.
Houtkooper RH; Rodenburg RJ; Thiels C; van Lenthe H; Stet F; Poll-The BT; Stone JE; Steward CG; Wanders RJ; Smeitink J; Kulik W; Vaz FM
Anal Biochem; 2009 Apr; 387(2):230-7. PubMed ID: 19454236
[TBL] [Abstract][Full Text] [Related]
29. FGF21 and GDF15 are elevated in Barth Syndrome and are correlated to important clinical measures.
Liu O; Chinni BK; Manlhiot C; Vernon HJ
Mol Genet Metab; 2023 Nov; 140(3):107676. PubMed ID: 37549445
[TBL] [Abstract][Full Text] [Related]
30. Diagnosis of Barth syndrome using a novel LC-MS/MS method for leukocyte cardiolipin analysis.
Bowron A; Frost R; Powers VE; Thomas PH; Heales SJ; Steward CG
J Inherit Metab Dis; 2013 Sep; 36(5):741-6. PubMed ID: 23109063
[TBL] [Abstract][Full Text] [Related]
31. Blocking phosphatidylglycerol degradation in yeast defective in cardiolipin remodeling results in a new model of the Barth syndrome cellular phenotype.
Káňovičová P; Čermáková P; Kubalová D; Bábelová L; Veselá P; Valachovič M; Zahumenský J; Horváth A; Malínský J; Balážová M
J Biol Chem; 2022 Jan; 298(1):101462. PubMed ID: 34864056
[TBL] [Abstract][Full Text] [Related]
32. Barth syndrome without tetralinoleoyl cardiolipin deficiency: a possible ameliorated phenotype.
Bowron A; Honeychurch J; Williams M; Tsai-Goodman B; Clayton N; Jones L; Shortland GJ; Qureshi SA; Heales SJ; Steward CG
J Inherit Metab Dis; 2015 Mar; 38(2):279-86. PubMed ID: 25112388
[TBL] [Abstract][Full Text] [Related]
33. The lipid environment modulates cardiolipin and phospholipid constitution in wild type and tafazzin-deficient cells.
Oemer G; Koch J; Wohlfarter Y; Lackner K; Gebert REM; Geley S; Zschocke J; Keller MA
J Inherit Metab Dis; 2022 Jan; 45(1):38-50. PubMed ID: 34494285
[TBL] [Abstract][Full Text] [Related]
34. Anomalous peroxidase activity of cytochrome c is the primary pathogenic target in Barth syndrome.
Kagan VE; Tyurina YY; Mikulska-Ruminska K; Damschroder D; Vieira Neto E; Lasorsa A; Kapralov AA; Tyurin VA; Amoscato AA; Samovich SN; Souryavong AB; Dar HH; Ramim A; Liang Z; Lazcano P; Ji J; Schmidtke MW; Kiselyov K; Korkmaz A; Vladimirov GK; Artyukhova MA; Rampratap P; Cole LK; Niyatie A; Baker EK; Peterson J; Hatch GM; Atkinson J; Vockley J; Kühn B; Wessells R; van der Wel PCA; Bahar I; Bayir H; Greenberg ML
Nat Metab; 2023 Dec; 5(12):2184-2205. PubMed ID: 37996701
[TBL] [Abstract][Full Text] [Related]
35. Cardiolipin deficiency affects respiratory chain function and organization in an induced pluripotent stem cell model of Barth syndrome.
Dudek J; Cheng IF; Balleininger M; Vaz FM; Streckfuss-Bömeke K; Hübscher D; Vukotic M; Wanders RJ; Rehling P; Guan K
Stem Cell Res; 2013 Sep; 11(2):806-19. PubMed ID: 23792436
[TBL] [Abstract][Full Text] [Related]
36. Tafazzin deficiency impairs CoA-dependent oxidative metabolism in cardiac mitochondria.
Le CH; Benage LG; Specht KS; Li Puma LC; Mulligan CM; Heuberger AL; Prenni JE; Claypool SM; Chatfield KC; Sparagna GC; Chicco AJ
J Biol Chem; 2020 Aug; 295(35):12485-12497. PubMed ID: 32665401
[TBL] [Abstract][Full Text] [Related]
37. Diverse mitochondrial abnormalities in a new cellular model of TAFFAZZIN deficiency are remediated by cardiolipin-interacting small molecules.
Anzmann AF; Sniezek OL; Pado A; Busa V; Vaz FM; Kreimer SD; DeVine LR; Cole RN; Le A; Kirsch BJ; Claypool SM; Vernon HJ
J Biol Chem; 2021 Sep; 297(3):101005. PubMed ID: 34314685
[TBL] [Abstract][Full Text] [Related]
38. Barth syndrome cells display widespread remodeling of mitochondrial complexes without affecting metabolic flux distribution.
Chatzispyrou IA; Guerrero-Castillo S; Held NM; Ruiter JPN; Denis SW; IJlst L; Wanders RJ; van Weeghel M; Ferdinandusse S; Vaz FM; Brandt U; Houtkooper RH
Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3650-3658. PubMed ID: 30251684
[TBL] [Abstract][Full Text] [Related]
39. Metabolic switch from fatty acid oxidation to glycolysis in knock-in mouse model of Barth syndrome.
Chowdhury A; Boshnakovska A; Aich A; Methi A; Vergel Leon AM; Silbern I; Lüchtenborg C; Cyganek L; Prochazka J; Sedlacek R; Lindovsky J; Wachs D; Nichtova Z; Zudova D; Koubkova G; Fischer A; Urlaub H; Brügger B; Katschinski DM; Dudek J; Rehling P
EMBO Mol Med; 2023 Sep; 15(9):e17399. PubMed ID: 37533404
[TBL] [Abstract][Full Text] [Related]
40. Loss of Mitochondrial Ca
Bertero E; Nickel A; Kohlhaas M; Hohl M; Sequeira V; Brune C; Schwemmlein J; Abeßer M; Schuh K; Kutschka I; Carlein C; Münker K; Atighetchi S; Müller A; Kazakov A; Kappl R; von der Malsburg K; van der Laan M; Schiuma AF; Böhm M; Laufs U; Hoth M; Rehling P; Kuhn M; Dudek J; von der Malsburg A; Prates Roma L; Maack C
Circulation; 2021 Nov; 144(21):1694-1713. PubMed ID: 34648376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
